IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL.

B Conclusions: b Early ibrutinib-treatment of patients with asymptomatic Binet stage A CLL at high risk of progression failed to demonstrate an overall survival benefit when compared to placebo. B Introduction: b We present the final analysis of the phase 3, double-blind, placebo-controlled CLL12 trial evaluating ibrutinib in patients with early stage CLL at increased risk of progression defined by a comprehensive score (NCT02863718). [Extracted from the article]